# KingsCrowd Capital's Investment into InvVax | InvVax

- Canonical URL: https://wefunder.com/feed/170186
- Entity ID: wefunder:feed_item:170186
- Published at: 2024-01-24 18:55:28 UTC
- Updated at: 2025-07-09 03:24:24 UTC

## Author
Arthur Young

## Subject
InvVax

## Content
Hello everyone,I'm excited to share some groundbreaking news with our InvVax community. KingsCrowd Capital has made a solid investment in InvVax during our current Wefunder round, and we've been awarded a stellar 4.3 rating on their platform. This is a monumental endorsement of our work and vision at InvVax.Understanding KingsCrowd CapitalKingsCrowd Capital is at the forefront of equity crowdfunding analysis, providing independent, AI-powered ratings and analytics for the online private market. Their commitment to identifying and supporting startups with significant potential makes their investment in InvVax particularly meaningful.Why KingsCrowd Capital Invested in UsKingsCrowd Capital's decision to invest was driven by their belief in our potential to revolutionize the pharmaceutical industry with our disruptive technology. Our approach to flu vaccination, which aims to provide protection from all flu strains and other diseases like COVID-19, HIV, and Hepatitis with just one shot every 3-5 years, represents a significant leap forward from current methods that require annual updates and guesses about prevalent strains.I invite you to read more about KingsCrowd Capital's investment and our vision for InvVax on the KingsCrowd rating page here. Our Vision and TechnologyThe journey to this point has been deeply personal and professional for me. Developing this technology during my postdoc at UCLA, rooted in my extensive background in Molecular Biology and Immunology, has been a challenging but rewarding journey. We've garnered significant support, raising funds from major angel groups and government agencies, which speaks volumes about the faith in our technology and its potential to change the world.The Future of InvVaxThe investment from KingsCrowd Capital is not just a financial boost but a validation of our valuation and the immense potential we have in the vast vaccine market. With a market size of over $122 billion, our journey is just beginning, and the path ahead is filled with opportunities to make a significant impact.A Limited Window to InvestAs we continue to advance our groundbreaking technology, I want to remind our community that there's only around $85k remaining in our early bird discount. This is a unique opportunity to invest in InvVax at a pivotal time in our journey. Don't wait too long to become part of this transformative venture that aims to redefine global health.Thank you for your continued support and belief in our mission. Together, we're not just developing a vaccine; we're working to safeguard the future of global health.Warm regards,Dr. Arthur Young